Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
CTR20211826Phase 3Completed
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Biotech Pharmaceutical Co., Ltd.. Started Sep 2021; status: completed.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20211826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211826.